OptumLabs Data Warehouse Research Articles

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.Design Retrospective, propensity matched cohort study.Setting:...

PD44-05 CONTEMPORARY NATIONAL TRENDS OF PROSTATE CANCER SCREENING AMONG PRIVATELY INSURED PATIENTS IN THE UNITED STATES

You have accessJournal of UrologyProstate Cancer: Detection and Screening IV1 Apr 2015PD44-05 CONTEMPORARY NATIONAL TRENDS OF PROSTATE CANCER SCREENING AMONG PRIVATELY INSURED PATIENTS IN THE UNITED STATES Simon Kim, R. Jeffrey Karnes, Cary Gross, Holly Van Houten, Robert Abouassaly, and Nilay Shah Simon KimSimon Kim More articles by this author , R. Jeffrey KarnesR. Jeffrey Karnes More articles by this author , Cary GrossCary Gross More articles by this author , Holly Van HoutenHolly Van Houten More articles by this author , Robert AbouassalyRobert Abouassaly More articles by this author , and Nilay ShahNilay Shah More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2551AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES With the recent changes to clinical practice guidelines for prostate cancer (PC) screening, little is known the degree to which PC screening with prostate-specific antigen (PSA) testing has changed, if at all. Therefore, we used a large private health insurance database to determine the national trends of PSA screening and investigate which patient characteristics associated with PSA testing. METHODS Using a large private health insurance claims database Optum Labs Data Warehouse), we identified males age 40-80 years who underwent PC screening from 2008 to 2013. The primary outcome was use of PSA testing among a privately insured population-based cohort. Demographic covariates included age, census region, race, education level and household income range. The Charlson/Deyo comorbidity index was calculated to assess comorbidity burden. Rates were calculated based on member-years and reported per 1,000 member-years. RESULTS Among the 11.6 million eligible enrollees, we identified 2.9 million (25%) men who underwent PSA screening from 2008 to 2013. The majority of the over 800,000 enrollees screened each year were white males, age 50-59 years residing in the Southern census region. The rate of men undergoing PSA screening remained stable from 190.4 per 1,000 member-years in 2008 to 196.4 in 2013 (p=0.66). Among enrollees aged 50 to 74 years old, PSA screening rates were relatively stable. However, enrollees who were > 75 years old had a marked decrease in PSA screening from 201.5 to 124.1 per 1,000 member-years from 2008 to 2013 (p=0.04). PSA screening rates did not vary by racial groups over time. CONCLUSIONS In this population-based cohort of privately insured men, we found little effect of PSA screening from changes to clinical practice guidelines overall except for men who were advanced age. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e899 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Simon Kim More articles by this author R. Jeffrey Karnes More articles by this author Cary Gross More articles by this author Holly Van Houten More articles by this author Robert Abouassaly More articles by this author Nilay Shah More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

PD44-06 CONFIDENCE IN BIOPSY FINDINGS IN THE ERA OF MRI-TARGETED PROSTATE SAMPLING

INTRODUCTION AND OBJECTIVES: With the recent changes to clinical practice guidelines for prostate cancer (PC) screening, little is known the degree to which PC screening with prostate-specific antigen (PSA) testing has changed, if at all. Therefore, we used a large private health insurance database to determine the national trends of PSA screening and investigate which patient characteristics associated with PSA testing. METHODS: Using a large private health insurance claims database Optum Labs Data Warehouse), we identified males age 40-80 years who underwent PC screening from 2008 to 2013. The primary outcome was use of PSA testing among a privately insured populationbased cohort. Demographic covariates included age, census region, race, education level and household income range. The Charlson/Deyo comorbidity index was calculated to assess comorbidity burden. Rates were calculated based on member-years and reported per 1,000 member-years. RESULTS: Among the 11.6 million eligible enrollees, we identified 2.9 million (25%) men who underwent PSA screening from 2008 to 2013. The majority of the over 800,000 enrollees screened each year were white males, age 50-59 years residing in the Southern census region. The rate of men undergoing PSA screening remained stable from 190.4 per 1,000 member-years in 2008 to 196.4 in 2013 (p1⁄40.66). Among enrollees aged 50 to 74 years old, PSA screening rates were relatively stable. However, enrollees who were > 75 years old had a marked decrease in PSA screening from 201.5 to 124.1 per 1,000 member-years from 2008 to 2013 (p1⁄40.04). PSA screening rates did not vary by racial groups over time. CONCLUSIONS: In this population-based cohort of privately insured men, we found little effect of PSA screening from changes to clinical practice guidelines overall except for men who were advanced age.

Use of the Optum Labs Data Warehouse to assess test ordering patterns for diagnosis of Helicobacter pylori infection in the United States.

We surveyed national Helicobacter pylori diagnostic testing practices and diagnoses using commercial and Medicare medical claims data from Optum Labs (Cambridge, MA). Serologic testing for antibodies to H. pylori remains the most commonly ordered diagnostic test despite recent expert recommendations. Changes in reimbursement for serologic testing will likely drive future provider ordering practices.